Nordic Capital, one of Europe’s most active private equity firms this year, agreed to invest 450 million euros ($535 million) in Danish dermatology firm LEO Pharma A/S.
The investment firm is buying a minority stake in LEO Pharma, according to a statement Tuesday, which didn’t disclose financial terms. The deal values LEO Pharma at about 3 billion euros including debt, people familiar with the matter said, asking not to be identified discussion confidential information.
LEO Pharma, a maker of topical medication for skin conditions, has been looking for a new investor since last year with the help of its advisers at Moelis & Co. The LEO Foundation will remain the majority shareholder of the company, according to the statement. A representative for Nordic Capital declined to comment on the valuation of the deal.
Source: Bloomberg
By Jan-Henrik Foerster
